Yuvti Tablet contains a combination of Ethinyl Estradiol (0.03 mg) and Drospirenone (3 mg), which are synthetic hormones used primarily for oral contraception. Ethinyl Estradiol is a synthetic estrogen, while Drospirenone is a synthetic progestin with anti-mineralocorticoid and anti-androgenic properties. This combination works by inhibiting ovulation, altering the cervical mucus to prevent sperm penetration, and modifying the endometrial lining to reduce the likelihood of implantation. Yuvti Tablet is indicated for the prevention of pregnancy in women seeking reliable contraceptive methods. It may also be prescribed for the management of menstrual disorders such as dysmenorrhea, menorrhagia, and to regulate menstrual cycles. The medication should be taken orally as directed by a healthcare professional, typically once daily at the same time each day to maintain consistent hormone levels. Contraindications include a history of thromboembolic disorders, hormone-sensitive malignancies, uncontrolled hypertension, and liver dysfunction. Common side effects may include nausea, headache, breast tenderness, and breakthrough bleeding. Patients should be advised to report any signs of thromboembolism, severe abdominal pain, or visual disturbances immediately. Yuvti Tablet is not suitable for use during pregnancy or lactation. Regular medical follow-up is recommended to monitor efficacy and safety during use.